BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Cipla
Johnson and Johnson
Chinese Patent Office
Baxter
Mallinckrodt
McKesson
Farmers Insurance
US Army
Chubb

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 202593

« Back to Dashboard

NDA 202593 describes CAPECITABINE, which is a drug marketed by Accord Hlthcare, Amneal Pharms, Mylan Pharms Inc, Shilpa Medicare Ltd, Teva Pharms Usa, and West-ward Pharms Int, and is included in six NDAs. It is available from twelve suppliers. Additional details are available on the CAPECITABINE profile page.

The generic ingredient in CAPECITABINE is capecitabine. There are twenty-eight drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the capecitabine profile page.
Summary for 202593
Tradename:CAPECITABINE
Applicant:Accord Hlthcare
Ingredient:capecitabine
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 202593
Medical Subject Heading (MeSH) Categories for 202593
Suppliers and Packaging for NDA: 202593
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CAPECITABINE capecitabine TABLET;ORAL 202593 ANDA Northstar RxLLC 16714-467 16714-467-01 60 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (16714-467-01)
CAPECITABINE capecitabine TABLET;ORAL 202593 ANDA Northstar RxLLC 16714-468 16714-468-01 120 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (16714-468-01)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength150MG
Approval Date:Apr 23, 2015TE:ABRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength500MG
Approval Date:Apr 23, 2015TE:ABRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Teva
AstraZeneca
Federal Trade Commission
Fish and Richardson
Fuji
Express Scripts
Queensland Health
Deloitte
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot